{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000010","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.375716+00:00","generated_at":"2026-05-15T05:11:02.221712+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma","bullets":["ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.","Median PFS 5.5 months; 42% progression-free at 6 months; DCR 87%.","Manageable safety, mostly Grade 1-2 diarrhea, fatigue, nausea; no significant liver toxicity despite 68% with liver metastases.","Plans to meet FDA in H2 2026 for first-line registrational trial; accelerate pathways for 4th-line CRC and refractory Ewing sarcoma.","BLA submitted to FDA for ozekibart in conventional chondrosarcoma in April 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000010","json":"https://secwatch.observer/filing/0002007919-26-000010.json","markdown":"https://secwatch.observer/filing/0002007919-26-000010.md","text":"https://secwatch.observer/filing/0002007919-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/0002007919-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/inhibrx-20260421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:11:02.221712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}